{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32", "Q2", 11195, "COVINGTON & BURLING LLP", 115253, "FABRE-KRAMER PHARMACEUTICALS, INC", 2016, "second_quarter", "2016-07-15T19:14:22.717000-04:00", null, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32/\", \"filing_uuid\": \"1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32\", \"filing_type\": \"Q2\", \"filing_type_display\": \"2nd Quarter - Report\", \"filing_year\": 2016, \"filing_period\": \"second_quarter\", \"filing_period_display\": \"2nd Quarter (Apr 1 - June 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32/print/\", \"filing_document_content_type\": \"text/html\", \"income\": null, \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Gary Heimberg\", \"dt_posted\": \"2016-07-15T19:14:22.717000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"850 10th Street, NW\", \"registrant_address_2\": null, \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20001\", \"registrant\": {\"id\": 11195, \"url\": \"https://lda.senate.gov/api/v1/registrants/11195/\", \"house_registrant_id\": 31827, \"name\": \"COVINGTON & BURLING LLP\", \"description\": \"Law firm\", \"address_1\": \"850 10th Street, NW\", \"address_2\": null, \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20001\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"BRIAN SMITH\", \"contact_telephone\": \"+1 202-662-5090\", \"dt_updated\": \"2026-01-26T21:21:48.674471-05:00\"}, \"client\": {\"id\": 115253, \"url\": \"https://lda.senate.gov/api/v1/clients/115253/\", \"client_id\": 1005395, \"name\": \"FABRE-KRAMER PHARMACEUTICALS, INC\", \"general_description\": \"Pharmaceutical company\", \"client_government_entity\": false, \"client_self_select\": null, \"state\": \"TX\", \"state_display\": \"Texas\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"TX\", \"ppb_state_display\": \"Texas\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2015-07-31\"}, \"lobbying_activities\": [{\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"Policy regarding demonstration of effectiveness for new drug approvals.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 62928, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"GARY\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"HEIMBERG\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32"], "units": {}, "query_ms": 2.8625470586121082, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}